Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has established itself as a leader in the development and commercialisation of innovative therapeutics, particularly in the areas of pain management and critical care.
Cumberland's core products, including Acetadote® and Vaprisol®, are distinguished by their unique formulations and targeted applications, addressing significant medical needs. With a commitment to improving patient outcomes, the company has achieved notable milestones, including successful product launches and strategic partnerships.
Cumberland Pharmaceuticals continues to strengthen its market position through a focus on research and development, ensuring its offerings remain at the forefront of the healthcare landscape.
-20 vs industry average
Cumberland Pharmaceuticals Inc.’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Cumberland Pharmaceuticals Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Cumberland Pharmaceuticals Inc. yet.
Cumberland Pharmaceuticals Inc.'s reported carbon emissions
Cumberland Pharmaceuticals Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi).
As a result, there are no significant achievements or targets to highlight regarding their carbon footprint or climate commitments. The lack of emissions data and reduction initiatives suggests that Cumberland Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Cumberland Pharmaceuticals Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Cumberland Pharmaceuticals Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project